NCT07390890 DSLT for Reducing Medication in Glaucoma
| NCT ID | NCT07390890 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Eye Institute of West Florida |
| Condition | Primary Open Angle Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-02-10 |
| Primary Completion | 2027-01-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2026-02-10 with a primary completion date of 2027-01-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.
Eligibility Criteria
Inclusion Criteria: * Adult patients scheduled to undergo DSLT treatment in one or both eyes. * Diagnosis of ocular hypertension or primary open angle glaucoma (POAG). * Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg. Exclusion Criteria: * Previous glaucoma surgeries/interventions: * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). * Patients who have undergone cataract surgery within the prior 2 years. * Secondary glaucoma: * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. * Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.
Contact & Investigator
Neel Desai, MD
PRINCIPAL INVESTIGATOR
The Eye Institute of West Florida
Frequently Asked Questions
Who can join the NCT07390890 clinical trial?
This trial is open to participants of all sexes, studying Primary Open Angle Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07390890 currently recruiting?
Yes, NCT07390890 is actively recruiting participants. Contact the research team at Renee.Bondurant@eyespecialist.com for enrollment information.
Where is the NCT07390890 trial being conducted?
This trial is being conducted at Largo, United States.
Who is sponsoring the NCT07390890 clinical trial?
NCT07390890 is sponsored by The Eye Institute of West Florida. The principal investigator is Neel Desai, MD at The Eye Institute of West Florida. The trial plans to enroll 60 participants.